Shanghai Henlius Biotech (HKG:2696) dosed the first patient in a Phase 1 clinical trial of HLX316 for injection, according to a Friday Hong Kong bourse filing.
The trial is studying the effects of the drug in patients with advanced/metastatic solid tumors in Mainland China.